Coastline Trust Co Sells 4,558 Shares of Zoetis Inc. $ZTS

Coastline Trust Co trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 86.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 739 shares of the company’s stock after selling 4,558 shares during the period. Coastline Trust Co’s holdings in Zoetis were worth $93,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Brighton Jones LLC grew its position in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC lifted its holdings in shares of Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after buying an additional 657 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after buying an additional 1,224 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares during the last quarter. Finally, FineMark National Bank & Trust grew its holdings in shares of Zoetis by 6.2% in the second quarter. FineMark National Bank & Trust now owns 2,604 shares of the company’s stock worth $406,000 after acquiring an additional 152 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ZTS shares. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, UBS Group set a $136.00 price objective on shares of Zoetis in a report on Thursday, January 29th. Six equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Price Performance

Shares of Zoetis stock opened at $115.43 on Friday. The stock has a market cap of $48.73 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 1.77 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a 50 day moving average price of $124.35 and a 200-day moving average price of $130.60. Zoetis Inc. has a one year low of $114.36 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.